Report of Foreign Issuer (6-k)
September 10 2019 - 7:00AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF
1934
September 2019
Commission File Number: 0001723069
Tiziana
Life Sciences plc
(Exact Name of Registrant as Specified in
Its Charter)
3rd Floor,
11-12 St James’s Square
London SW1Y 4LB
United Kingdom
(Address of registrant’s principal
executive office)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT
ON FORM 6-K
On September 10, 2019, Tiziana Life Sciences
plc (the “Company”) issued a regulatory news service announcement in the United Kingdom Reporting Phase 1 Clinical
Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers of Immunomodulation
and Anti-inflammation in Healthy Volunteers (the “RNS Announcement”).
The RNS Announcement is furnished herewith
as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibit 99.1 is being furnished and shall not
be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject
to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the
Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be
expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
TIZIANA LIFE SCIENCES PLC
|
|
|
Date: September 10, 2019
|
By:
|
/s/ Kunwar Shailubhai
|
|
|
Name:
|
Kunwar Shailubhai
|
|
|
Title:
|
Chief Executive Officer
|
EXHIBIT INDEX
3
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Sep 2023 to Sep 2024